Already a member? Sign in
Category: Prescription Drugs
Most Popular Types: Macrodantin, Macrobid, Nitrofuran MAC (Show all)
Nitrofurantoin is an antibiotic that is used to prevent and treat urinary tract infections caused by susceptible strains of E. coli, S. aureus, Enterococcus, Klebsiella, and Enterobacter.
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| Bladder problems | 38 | 5 |
|
|
|
||
| Prevent infection | 24 | 4 |
|
|
|||
| Urinary Tract Infection UTI | 24 | 13 |
|
|
|
|
|
| Other | 14 | 3 |
|
|
|||
| Support urinary health | 3 | 1 |
|
||||
| Recurring Urinary Tract Infection UTI | 2 | 0 |
See all 86 patients currently taking Nitrofurantoin
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Nitrofurantoin
| Fatigue | 1 | |
|---|---|---|
| Excessive daytime sleepiness (somnolence) | 1 | |
| Yeast Infection (candida) | 1 | |
| Diarrhea chronic | 1 | |
| Stomach problems | 1 |
Frequently reported dosages based on patients currently taking Nitrofurantoin. See all 20 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Course of treatment ended | 25 | ||
| Doctor's advice | 7 | ||
| Other | 5 | ||
| Side effects too severe | 2 | ||
| Did not seem to work | 1 | ||
| Personal research | 1 |
Adherence
Taking treatment as prescribed
Adherence of Nitrofurantoin
Always |
21 | 78% |
|
|---|---|---|---|
Usually |
4 | 15% |
|
Sometimes |
1 | 4% |
|
Never |
1 | 4% |
|
Burden
Difficulty being on treatment
Burden of Nitrofurantoin
Very |
0 | 0% |
|
|---|---|---|---|
Somewhat |
2 | 7% |
|
A little |
3 | 11% |
|
Not at all |
22 | 81% |
|
Cost
Paid out of pocket
Cost of Nitrofurantoin
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
0 | 0% |
|
$50-99 |
1 | 7% |
|
$25-49 |
1 | 7% |
|
< $25 |
13 | 87% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 11, 2012.